Ekso Bionics Holdings, Inc. (EKSO) Downgraded to “Hold” at Zacks Investment Research
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued on Thursday.
According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “
Separately, B. Riley restated a “buy” rating and issued a $4.00 price objective on shares of Ekso Bionics Holdings in a research note on Monday, May 15th.
Ekso Bionics Holdings (NASDAQ:EKSO) traded up 0.17% during mid-day trading on Thursday, reaching $1.26. The company’s stock had a trading volume of 273,517 shares. The company has a 50 day moving average of $1.67 and a 200-day moving average of $2.37. Ekso Bionics Holdings has a 52-week low of $0.99 and a 52-week high of $6.38. The stock’s market cap is $32.49 million.
In other Ekso Bionics Holdings news, insider Russ Angold sold 221,746 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The stock was sold at an average price of $1.55, for a total value of $343,706.30. Following the sale, the insider now owns 400,678 shares in the company, valued at $621,050.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders sold 259,352 shares of company stock worth $399,373 in the last 90 days. Corporate insiders own 7.10% of the company’s stock.
A number of hedge funds have recently added to or reduced their stakes in the stock. Carl Domino Inc raised its stake in Ekso Bionics Holdings by 74.7% in the second quarter. Carl Domino Inc now owns 82,054 shares of the company’s stock valued at $190,000 after buying an additional 35,088 shares in the last quarter. Intellectus Partners LLC raised its stake in Ekso Bionics Holdings by 5.3% in the second quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock valued at $244,000 after buying an additional 5,294 shares in the last quarter. National Planning Corp raised its stake in Ekso Bionics Holdings by 116.2% in the second quarter. National Planning Corp now owns 234,450 shares of the company’s stock valued at $537,000 after buying an additional 126,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Ekso Bionics Holdings by 32.9% in the second quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock valued at $1,650,000 after buying an additional 176,197 shares in the last quarter. Finally, Independence Advisors LLC acquired a new stake in Ekso Bionics Holdings during the second quarter valued at about $1,840,000. Hedge funds and other institutional investors own 6.04% of the company’s stock.
Ekso Bionics Holdings Company Profile
Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.
Receive News & Stock Ratings for Ekso Bionics Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics Holdings Inc. and related stocks with our FREE daily email newsletter.